Featured News
GLP-1 Receptor Agonists for a Safer Future
GLP-1 and Chronic Disease Management
For millions living with obesity, type 2 diabetes, and related metabolic disorders, GLP-1 receptor agonists (GLP-1RAs) have revolutionized modern medicine. These therapies deliver transformative clinical benefits, including improved glycemic control, sustained weight loss, cardiovascular protection, and enhanced quality of life. Their rapid global adoption marks a turning point in how chronic diseases are treated and prevented, underscoring growing confidence in their ability to enhance long-term metabolic and cardiovascular health.
Ensuring Long-Term Safety and Metabolic Resilience
As GLP-1 therapies evolve and treatment durations increase, the focus is shifting increasingly toward the question of long-term safety. Researchers are closely examining how these agents influence lean mass preservation, bone density, and sex-specific toxicology profiles, as well as the broader endocrine and metabolic effects that accompany prolonged use. Strengthening the body of evidence in these areas is essential to realizing the full therapeutic and preventive potential of GLP-1 receptor agonists, ensuring that their promise is matched by a sustained commitment to the well-being of patients as well as scientific rigor.
Beyond Treatment: Preventing Metabolic Decline
The growth of GLP-1 therapies is fueling a new era of preventive medicine, aiming to stop obesity-related and cardiometabolic diseases before they develop. Research into mitochondrial health, muscle-preserving strategies, gut-hormone modulation, and personalized nutrition are paving the way for proactive care.
GLP-1 Drugs: Beyond Obesity
See how GLP-1s currently help manage diabetes and obesity, and how they could be used to eventually treat Alzheimer’s, addiction, Parkinson’s, autoimmune disease, and NASH.
Watch Now
Emerging findings also suggest that GLP-1RAs may be repurposed for use beyond metabolic disorders as early research has indicated potential benefits in neuropsychiatric conditions. However, continued mechanistic and clinical exploration is needed to translate this promise into real-world impact.
Advancing Safe and Effective GLP-1 Therapies
As this next chapter unfolds, our previous experience of supporting several GLP-1 programs currently on the market with chronic toxicology, coupled with a proven track record in long-term safety programs spanning multiple modalities and therapeutic areas, demonstrates our commitment to scientific excellence and patient-centered innovation.
We're dedicated to help innovators develop GLP-1 receptor agonists that are effective, safe for long-term use, and can potentially be repurposed in other therapeutic areas. By prioritizing patient well-being and metabolic resilience, we can shape a future where chronic diseases are managed proactively and compassionately.
Let's Advance Chronic Disease Care Together
Because every moment matters, time is of the essence, and patients need your therapeutic. Find out how our scientific and regulatory expertise can accelerate your next GLP-1 breakthrough.